Resources Repository
-
ArticlePublication 2009Cost-Effectiveness of Rotavirus Vaccination in Vietnam
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, …
This article reports on a cost-effectiveness analysis of rotavirus vaccination, including varying degrees of severity, age-dependency of clinical manifestation, and additional features of the disease (e.g., the possibility of reinfection and varying degrees of partial immunity conferred by natural infection). The authors developed a Markov model that reflects key features of rotavirus infection, using the most recent data available at the time of their analysis. They applied the model to the 2004 Vietnamese birth cohort…
Calibration/Validation | Health/Medicine | Health Systems | Mathematical Models | Cost-Effectiveness Analysis | Infectious Diseases | Child/Nutrition | Asia & Pacific -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Calibration/Validation | Health/Medicine | Health Systems | Dynamic Transmission | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology | North America -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Calibration/Validation | Health/Medicine | Health Systems | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Science/Technology | Asia & Pacific -
ArticlePublication 2008Health and Economic Impact of HPV 16 and 18 Vaccination and Cervical Cancer Screening in India
As cervical cancer is a leading cause of cancer death among women in low-income countries, …
As cervical cancer is a leading cause of cancer death among women in low-income countries, with approximately 25% of cases worldwide occurring in India, these authors estimated the potential health and economic impact of different cervical cancer prevention strategies in India. After empirically calibrating a cervical cancer model to country-specific epidemiologic data, they projected cancer incidence, life expectancy, and lifetime costs (I$2005), and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of…
Calibration/Validation | Health/Medicine | Health Systems | Microsimulation | Cost-Effectiveness Analysis | Infectious Diseases | Chronic Disease/Risk | Clinical Care | Economics/Finance | Science/Technology | Asia & Pacific -
BookPublication 2003WHO Guide to Cost-Effectiveness Analysis
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an …
This 2003 guide provides a method of assessing the cost-effectiveness of health interventions for an international audience. The authors aim to inform the policy maker and to maximize the generalizability of results across settings. Part I begins with a description of cost-effectiveness analysis. It then considers issues relating to study design, estimating costs, assessing health effects, discounting, uncertainty and sensitivity analysis, and reporting results. Part II provides examples to illustrate the principles in Part I. Detailed discussions…
Priority Setting/Ethics | Health/Medicine | Health Systems | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | Cost-Effectiveness Analysis | Global -
BookPublication 1996Cost-Effectiveness in Health and Medicine, 1st Edition
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and …
In 1993, the US Public Health Service convened a panel of 13 nongovernment scientists and scholars with expertise in economics, clinical medicine, ethics, and statistics to review the state of cost-effectiveness analysis and to develop recommendations for its conduct and use in health and medicine. Publishing their results in 1996, they proposed the most explicit set of guidelines (together with their rationale) ever defined on the conduct of CEAs. The panel recommended analysts include a "reference-case"…
Priority Setting/Ethics | Health/Medicine | Health Systems | Preferences/Values | Costing Methods | Health Outcomes | Evidence Synthesis | Value of Information | Cost-Effectiveness Analysis | Policy/Regulation | Economics/Finance | North America